Dyspnea review for the palliative care professional: Treatment goals and therapeutic options

Journal of Palliative Medicine

Volumn 15, Issue 1, 2012, Pages 106-114

  Kamal, Arif H ^a   Maguire, Jennifer M ^b   Wheeler, Jane L ^a   Currow, David C ^c   Abernethy, Amy P ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; FENTANYL; FUROSEMIDE; HELIOX; HYDROMORPHONE; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; NALOXONE; OPIATE; SEROTONIN UPTAKE INHIBITOR;

ACUPUNCTURE; ADVANCED CANCER; ARTERIAL CARBON DIOXIDE TENSION; ASTHMA; BREATHING RATE; BRONCHOSPASM; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXERCISE TOLERANCE; FOLLOW UP; HUMAN; HYPERCAPNIA; INSOMNIA; LIFE EXPECTANCY; LUNG VOLUME; META ANALYSIS (TOPIC); NEOPLASM; OXYGEN CONSUMPTION; OXYGEN SATURATION; OXYGEN THERAPY; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PLEURECTOMY; PROSPECTIVE STUDY; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREADMILL EXERCISE; TREATMENT OUTCOME; TREATMENT RESPONSE;

DYSPNEA; GOALS; HUMANS; PALLIATIVE CARE;

EID: 84856354282     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0110     Document Type: Review

References (78)

1. Kaye AD, Hoover JM, Ibrahim IN, Phelps J, Baluch A, Fields A, Huffman S: Analysis of the effects of fentanyl in the feline pulmonary vascular bed. Am J Ther 2006;13:478-484. (Pubitemid 44813676)
2. Tenore PL: Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 2008;27:49-65.
3. Mahler DA, Murray JA, Waterman LA, Ward J, Kraemer WJ, Zhang X, Baird JC: Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 2009;33:771-777.
4. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE: A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939-944. (Pubitemid 35316271)
5. Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Semmer SM: Interventions for alleviating cancer-related dyspnea: A systematic review. J Clin Oncol 2008;26:2396-2404.
6. Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RK: The management of dyspnea in cancer patients: A systematic review. Support Care Cancer 2008;16:329-337.
7. Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J: Nebulized versus subcutaneous morphine for patients with cancer dyspnea: A preliminary study. J Pain Symptom Manage 2005;29:613-618. (Pubitemid 40826484)
8. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C: Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-528.
9. Allard P, Lamontagne C, Bernard P, Tremblay C: How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999;17:256-265. (Pubitemid 29159968)
10. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ, Abernethy AP: Once-daily opioids for chronic dyspnea: A dose increment and phar-macovigilance study. J Pain Symptom Manage 2011;42:388-389.
11. Clemens KE, Klaschik E: Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Support Care Cancer 2008;16:93-99. (Pubitemid 350243764)
12. Charles MA, Reymond L, Israel F: Relief of incident dyspnea in palliative cancer patients: A pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hy-dromorphone, and nebulized saline. J Pain Symptom Manage 2008;36:29-38.
13. Smith TJ, Coyne P, French W, Ramakrishnan V, Corrigan P: Failure to accrue to a study of nebulized fentanyl for dyspnea: Lessons learned. J Palliat Med 2009;12:771-772.
14. Benitez-Rosario MA, Martin AS, Feria M: Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. J Pain Symptom Manage 2005;30:395-397. (Pubitemid 41718958)
15. Gauna AA, Kang SK, Triano ML, Swatko ER, Vanston VJ: Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: An observational case series. J Palliat Med 2008;11:643-648. (Pubitemid 351630193)
16. Wilson RH, Hoseth W, Dempsey ME: Respiratory acidosis. I. Effects of decreasing respiratory minute volume in patients with severe chronic pulmonary emphysema, with specific reference to oxygen, morphine and barbiturates. Am J Med 1954;17:464-470.
17. Clemens KE, Quednau I, Klaschik E: Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008;11:204-216. (Pubitemid 351374202)
18. Clemens KE, Klaschik E: Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 2007;33:473-481. (Pubitemid 46482946)
19. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR, Ely EW, Hansen-Flaschen J, O'Donnell DE, Waller A: American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010;137:674-691.
20. Mitchell-Heggs P, Murphy K, Minty K, Guz A, Patterson SC, Minty PS, Rosser RM: Diazepam in the treatment of dyspnoea in the 'Pink Puffer' syndrome. Q J Med 1980;49:9-20. (Pubitemid 10039097)
21. Eimer M, Cable T, Gal P, Rothenberger LA, McCue JD: Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract 1985;21:359-362. (Pubitemid 16220783)
22. Man GC, Hsu K, Sproule BJ: Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986;90:832-836. (Pubitemid 17196171)
23. Woodcock AA, Gross ER, Geddes DM: Drug treatment of breathlessness: Contrasting effects of diazepam and pro-methazine in pink puffers. Br Med J (Clin Res Ed) 1981;283: 343-346. (Pubitemid 12250669)
24. Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME: Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006;31: 38-47. (Pubitemid 43143297)
25. Navigante AH, Castro MA, Cerchietti LC: Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010;39:820-830.
26. Currow DC, Abernethy AP: Potential opioid-sparing effect of regular benzodiazepines in dyspnea: Longer duration of studies needed. J Pain Symptom Manage 2010;40:e1-e2; author reply e2-e4.
27. Wilcock A, Walton A, Manderson C, Feathers L, El Khoury B, Lewis M, Chauhan A, Howard P, Bell S, Frisby J, Tat-tersfield A: Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008;63:872-875.
28. Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, Shima Y, Uchitomi Y: Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003;26:962-967. (Pubitemid 37188470)
29. Ong KC, Kor AC, Chong WF, Earnest A, Wang YT: Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1028-1033. (Pubitemid 38543642)
30. Nishino T, Ide T, Sudo T, Sato J: Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000;161:1963-1967. (Pubitemid 30418137)
31. Jensen D, Amjadi K, Harris-McAllister V, Webb KA, O'Donnell DE: Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008;63:606-613. (Pubitemid 351969253)
32. Stone P, Rix, Kurowska A, Tookman: Re: nebulized furose-mide for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002;24:274-275; author reply 275-276.
33. Shimoyama N, Shimoyama M: Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002;23:73-76. (Pubitemid 34093886)
34. Stone P, Kurowska A, Tookman A: Nebulized frusemide for dyspnoea. Palliat Med 1994;8:258.
35. Roberts CM: Short burst oxygen therapy for relief of breathlessness in COPD. Thorax 2004;59:638-640. (Pubitemid 39061522)
36. Escalante CP, Martin CG, Elting LS, Cantor SB, Harle TS, Price KJ, Kish SK, Manzullo EF, Rubenstein EB: Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care world. Cancer 1996;78:1314-1319. (Pubitemid 26303900)
37. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391-398.
38. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1:681-686.
39. Eaton T, Lewis C, Young P, Kennedy Y, Garrett JE, Kolbe J: Long-term oxygen therapy improves health-related quality of life. Respir Med 2004;98(4):285-293. (Pubitemid 38443687)
40. Cranston JM, Crockett A, Currow D: Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev 2008;(3): CD004769.
41. Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP: Oxygen for relief of dyspnoea in mildly-or non-hypoxaemic patients with cancer: A systematic review and meta-analysis. Br J Cancer 2008;98:294-299. (Pubitemid 351161251)
42. Currow DC, Fazekas B, Abernethy AP: Oxygen use-patients define symptomatic benefit discerningly. J Pain Symptom Manage 2007;34:113-114. (Pubitemid 47088907)
43. Uronis HE, Currow DC, Abernethy AP: Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:289-304.
44. Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS: Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med 2007;176:343-349. (Pubitemid 47267467)
45. Clemens KE, Quednau I, Klaschik E: Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: A prospective study. Support Care Cancer 2009;17:367-377.
46. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE 2nd, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler JL, Tulsky JA, Crockett AJ, Currow DC: Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: A double-blind, randomised controlled trial. Lancet 2010;376:784-793.
47. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S: Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010;39:831-838.
48. Casaburi R, ZuWallack R: Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009;360:1329-1335.
49. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, Zuwallack R, Herrerias C: Pulmonary rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007;131 (5 Suppl):4S-42S. (Pubitemid 46744215)
50. Riesenberg H, Lubbe AS: In-patient rehabilitation of lung cancer patients-a prospective study. Support Care Cancer 2010;18:877-882.
51. Morris GS, Gallagher GH, Baxter MF, Brueilly KE, Scheetz JS, Ahmed MM, Shannon VR: Pulmonary rehabilitation improves functional status in oncology patients. Arch Phys Med Rehabil 2009;90:837-841.
52. Fan VS, Giardino ND, Blough DK, Kaplan RM, Ramsey SD: Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial. COPD 2008;5:105-116. (Pubitemid 351549832)
53. Bausewein C, Booth S, Gysels M, Higginson I: Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008;(2):CD005623.
54. Monsky WL, Yoneda KY, MacMillan J, Deutsch LS, Dong P, Hourigan H, Schwartz Y, Magee S, Duffield C, Boak T, Cernilia J: Peritoneal and pleural ports for management of refractory ascites and pleural effusions: Assessment of impact on patient quality of life and hospice/home nursing care. J Palliat Med 2009;12:811-817.
55. Olden AM, Holloway R: Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010;13:59-65.
56. Amjadi K, Voduc N, Cruysberghs Y, Lemmens R, Fergusson DA, Doucette S, Noppen M: Impact of interventional bron-choscopy on quality of life in malignant airway obstruction. Respiration 2008;76:421-428.
57. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ
58. Sciurba FC, Tonascia J, Fishman AP; National Emphysema Treatment Trial Research Group: Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006;82:431-443.
59. Snyder ML, Goss CH, Neradilek B, Polissar NL, Mosenifar Z, Wise RA, Fishman AP, Benditt JO; National Emphysema Treatment Trial Research Group: Changes in arterial oxygen-ation and self-reported oxygen use after lung volume reduction surgery. Am J Respir Crit Care Med 2008;178:339-345.
60. Washko GR, Fan VS, Ramsey SD, Mohsenifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, Reilly JJ; National Emphysema Treatment Trial Research Group: The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;177:164-169.
61. Naunheim KS, Wood DE, Krasna MJ, DeCamp MM Jr, Ginsburg ME, McKenna RJ Jr, Criner GJ, Hoffman EA, Sternberg AL, Deschamps C; National Emphysema Treatment Trial Research Group: Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg 2006;131:43-53. (Pubitemid 43049782)
62. Chiappa GR, Queiroga F Jr, MedaE, Ferreira LF, Diefenthaeler F, Nunes M, Vaz MA, Machado MC, Nery LE, Neder JA: Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1 2009;179:1004-1010.
63. Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V: A double-blind, randomised, controlled Phase II trial of He-liox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004;90:366-371. (Pubitemid 38250630)
64. Manthous C, Morgan SM, Pohlnian A, Hall JB: Heliox in the treatment of airflow obstruction: A critical review of the literature. Respiratory Care 1997;42:1034-1042. (Pubitemid 27518207)
65. Jobst K, Chen JH, McPherson K, Arrowsmith J, Brown V, Efthimiou J, Fletcher HJ, Maciocia G, Mole P, Shifrin K, Lane D: Controlled trial of acupuncture for disabling breathless-ness. Lancet 1986;2:1416-1419. (Pubitemid 17217924)
66. Lewith GT, Prescott P, Davis CL: Can a standardized acupuncture technique palliate disabling breathlessness: A single-blind, placebo-controlled crossover study. Chest.2004;125: 1783-1790. (Pubitemid 38648412)
67. Filshie J, Penn K, Ashley S, Davis CL: Acupuncture for the relief of cancer-related breathlessness. Palliat Med 1996;10:145-150. (Pubitemid 26110995)
68. Wilson DO, Rogers RM, Wright EC, Anthonisen NR: Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989;139: 1435-1438. (Pubitemid 19155503)
69. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM: Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 2003;19:120-127. (Pubitemid 36196765)
70. Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FC, Wou-ters EF: Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998;52:396-401. (Pubitemid 28284776)
71. Engelen MP, Deutz NE, Wouters EF, Schols AM: Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162(4 Pt 1):1488-1492.
72. Morrison WL, Gibson JN, Scrimgeour C, Rennie MJ: Muscle wasting in emphysema. Clin Sci (Lond) 1988;75:415-420.
73. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS: Nutritional support for individuals with COPD: a meta-analysis. Chest 2000;117:672-678. (Pubitemid 30152204)
74. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J: Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(2): CD000998.
75. Puhan MA, Scharplatz M, Troosters T, Steurer J: Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality-a systematic review. Respir Res 2005;6:54.
76. Sugawara K, Takahashi H, Kasai C, Kiyokawa N, Watanabe T, Fujii S, Kashiwagura T, Honma M, Satake M, Shioya T: Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. Respir Med 2010;104:1883-1889.
77. Nishino T, Iiyori N, Isono S, Shinozuka N, Taguchi N, Ish-ikawa T: THAM improves an experimentally induced severe dyspnea. J Pain Symptom Manage 2009;37:212-219.
78. Taguchi N, Ishikawa T, Sato J, Nishino T: Effects of induced metabolic alkalosis on perception of dyspnea during flow-resistive loading. J Pain Symptom Manage 1996;12:11-17. (Pubitemid 26187519)